Thanks for posting. Imugene, close to if not the worst performing biotech stock on the index. In other words people have lost more money in investing in Imugene (IMU ASX) than practically any other biotech in Australia.
Imugene continues to play the long game. Their science may pull off. Perhaps it even is. But clearly from a monetary perspective something needs to change. By analysing the leading performers in this table, from CU6 to NEU, pearls of wisdom can be gained to take back to Team Imugene, from which to map a profitable path forward. Are they going to fall in line and do what it takes to turn things around? Or are they going to continue on in their single minded pursuit of scientific goals at whatever the cost for their owners and retail shareholders?
It's not a game anymore. Imugene have realised some achievements in breaking down the wall that encircles solid tumour treatment. Yet their executive's failure to strike a commercial blow with Her Vaxx and most importantly PD1 Vaxx, leads me to the conclusion that unless there is systemic change at the board level with a clear focus on the commercialisation of the stock, then Imugene runs the risk of taking out the wooden spoon next year, irrespective of what they achieve on the science field. As is clearly evident by the strong gains from those on your table, there is more to biotech investing than clinical trial results. Establishing strong distribution and supply agreements, as Clarity and Neuren have done, has enabled them to continue the development of their prostrate cancer and Rhetts Syndrome drugs in the knowledge they have the support of strong partners. Reaching such agreements and then communicating them effectively and what they mean for shareholders, has been the key to their success.
Unfortunately no-one holding Imugene can say with confidence who their prospective partner is or what they may look like, where if anywhere or with whom they plan on distributing their drugs, how they are going to fund their drug development post 2025, or when if ever they are going to prioritise their B cell platform again. These issues are clearly not on the radar of LC and PH, as they carry forward on their single minded mission to take Vaxinia and Oncarlytics as far as they can for as long as they can, to unlock what is potentially the gateway or holy grail of cancer treatment, that being solid tumour eradication in humans. But it is clearly, as highlighted by the underwhelming performance on your table, an issue at the forefront of those in the market. Investors require ongoing facts, figures, deliverables and agreements from which to hang their investment dollars on. Not the hope and promise of things to come. You can be as excited and as exuberant as you like at the start of a PD1 Vaxx Trial, or a collaboration with a life sciences entity, but unless these endeavours conclude in a a commercial outcome than its all just bluff and bluster in the eyes of those making the investment decisions on Wall Street, or any street for that matter.
Let's not be too negative though. If the board makes some executive changes to key personnel, meets their primary endpoints in the ongoing Azer cel trial, identifies one more indication to commence another fast track designation in the Vaxinia (MAST) Trial and perhaps triggers some positive immune responses in their Phase 1 Oncarlytics Trial, then even blind Freddie may be in a position to ink a commercial deal for one or all of these promising treatment arms. If so Imugene may be in a position to make the Top 4 on next years leaderboard. Let's wait and see.......
DYOR Seek investment advice as and when required Opinions only
(20min delay)